*This course has been retired. Please click here for new course: COVID NIH Treatment Guidelines.
U.S. Department of Health and Human Services
The hyperactive inflammatory response to SARS-CoV-2 infection plays a central role in the pathogenesis of COVID-19. This section includes information on the use of the following immunomodulators for hospitalized patients, depending on disease severity: corticosteroids: (dexamethasone); Interleukin-6 inhibitors: (tocilizumab or sarilumab); Janus kinase (JAK) inhibitors: baricitinib (or tofacitinib).
This section includes additional recommendations about other immunomodulators with insufficient information to make a recommendation and guidance about immunomodulators that the Panel recommends against.
- Click on the PDF link below to access this section.
- Return to this page. Click “Next” below access the next section.
- The last section provides a link to the quiz, registration, payment, and certificate.